- JP-listed companies
- Cash flow
(130A) Cash flow
Market cap
¥3.1B
P/E ratio
-5.4x
Veritas In Silico develops small-molecule drugs targeting messenger RNA using its ibVIS platform, partnering with major pharmaceutical companies like Takeda and Shionogi.
| 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 18 | 30 | 27 | 16 | 16 |
| Cash from operations | -235 | -149 | 69 | -218 | -299 |
| Capital expenditures | -3 | -55 | -2 | -6 | -26 |
| Cash from investing | 8 | -56 | -2 | -2,006 | 451 |
| Cash from financing | 1,395 | - | -2 | 848 | - |